2024
Deep learning to decode sites of RNA translation in normal and cancerous tissues.
Clauwaert J, McVey Z, Gupta R, Yannuzzi I, Menschaert G, Prensner J.R.
Preprint available on BioRxiv.
A road map for the treatment of pediatric diffuse midline glioma.
Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M, Franson A, Galban S, Garcia Moure M, Garton H, Gowda P, Marques JG, Hawkins C, Heath A, Hulleman E, Ji S, Jones C, Kilburn L, Kline C, Koldobskiy MA, Lim D, Lowenstein PR, Lu QR, Lum J, Mack S, Magge S, Marini B, Martin D, Marupudi N, Messinger D, Mody R, Morgan M, Mota M, Muraszko K, Mueller S, Natarajan SK, Nazarian J, Niculcea M, Nuechterlein N, Okada H, Opipari V, Pai MP, Pal S, Peterson E, Phoenix T, Prensner JR, Pun M, Raju GP, Reitman ZJ, Resnick A, Rogawski D, Saratsis A, Sbergio SG, Souweidane M, Stafford JM, Tzaridis T, Venkataraman S, Vittorio O, Wadden J, Wahl D, Wechsler-Reya RJ, Yadav VN, Zhang X, Zhang Q, Venneti S. Cancer Cell. 2024 Jan 8;42(1):1-5. doi: 10.1016/j.ccell.2023.11.002. Epub 2023 Nov 30. PMID: 38039965
Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.
Hofman DA, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser KR, Condurat AL, van Dinter JT, Engels SAG, Goodale A, van der Lugt J, Abid T, Wang L, Zhou KN, Vogelzang J, Ligon KL, Phoenix TN, Roth JA, Root DE, Hubner N, Golub TR, Bandopadhayay P, van Heesch S, Prensner JR. Molecular Cell. 2024 Jan 18;84(2):261-276.e18. doi: 10.1016/j.molcel.2023.12.003. Epub 2024 Jan 3.PMID: 38176414
2023
Shining a light on the dark proteome: Non-canonical open reading frames and their encoded miniproteins as a new frontier in cancer biology.
Posner Z., Yannuzzi I., Prensner J.R.. Shining a light on the dark proteome: Non-canonical open reading frames and their encoded miniproteins as a new frontier in cancer biology. Protein Science. 2023 Jun 23;e4708. doi: 10.1002/pro.4708. Online ahead of print. PMID: 37350227
What can Ribo-seq and proteomics tell us about the non-canonical proteome?
Prensner J.R., Abelin J.G., Kok L.W., Clauser K.R., Mudge J.M., Ruiz-Orera J., Bassani-Sternberg M., Moritz R.L., Deutsch E.W., van Heesch S. Molecular & Cellular Proteomics. 2023, in press https://doi.org/10.1016/j.mcpro.2023.100631Interactome profiling implicates small peptides and young microproteins translated from human short open reading frames in essential biological processes.
Sandmann C.L., Schulz J.F., Ruiz-Orera, J., Kirchner M., Ziehm M., Adami E., Marczenke M., Liebe N., Greiner J., Schoenenberger A., Muecke M.B., Liang N., Mudge J.M., Prensner J.R., Willnow T.E., Mertins P., van Heesch S., Hubner N. Interactome profiling implicates small peptides and young microproteins translated from human short open reading frames in essential biological processes. Molecular Cell, 2023 Feb 14;S1097-2765(23)00075-8. doi: 10.1016/j.molcel.2023.01.023. Online ahead of print. PMID: 36806354
2022
Standardized annotation of translated open reading frames.
Mudge, J.M.*, Ruiz-Orera, J.*, Prensner J.R.*, Brunet M.A., Calvet F., Jungreis I., Gonzalez J.M., Magrane M., Martinez T.F., Schulz J.F., Yang Y.T., Albà M.M., Aspden J.L., Baranov P.V., Bazzini A., Bruford E., Martin M.J., Calviello L., Carvunis A.R., Chen J., Couso J.P., Deutsch E.W., Flicek P., Frankish A., Gerstein M., Hubner N., Ingolia N.T., Kellis M., Menschaert G., Moritz R.L., Ohler U., Roucou X., Saghatelian A., Weissman J., van Heesch S. Standardized annotation of translated open reading frames. Nature Biotechnology, 2022 Jul;40(7):994-999 doi: 10.1038/s41587-022-01369-0. PMID: 35831657 *These authors contributed equally
2021
Non-canonical open read frames encode functional proteins essential for cancer cell survival.
Prensner J.R., Enache O.M., Luria V., Krug K., Clauser K.R., Dempster J.M., Karger A., Wang L., Stumbraite K., Wang V.M., Botta G., Lyons N.J., Goodale A., Kalani Z., Fritchman B., Brown A., Alan D., Green T., Yang X., Jaffe J.D., Roth J.A., Piccioni F., Kirschner M.W., Root D.E., Golub, T.R. Non-canonical open read frames encode functional proteins essential for cancer cell survival. Nature Biotechnology, 2021 Jun;39(6):697-704. doi: 10.1038/s41587-020-00806-2. Epub 2021 Jan 28. PMID: 33510483
A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: opportunities for precision medicine.
Prensner J.R., Putra J., Vargas S.O., Church A.J., Janeway K.A., McCleary N.J., DuBois S.G. A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: opportunities for precision medicine. Pediatric Blood & Cancer, 2021 Apr; 68(4):e28780. doi:10.1002/pbc.28780. PMID: 33314665.
2020
Safety and efficacy of Gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: report of four pediatric cases.
Takahashi T.*, Prensner J.R.*, Robson C.D., Janeway K.A., Weigel B.J. Safety and efficacy of Gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: report of four pediatric cases. Pediatric Blood & Cancer, 2020 Oct; 67(10):e28636. DOI: 10.1002/pbc.28636; PMID 32762028. *These authors contributed equally
An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation.
Brucker WJ*, Croteau SE*, Prensner JR*, Cullion K, Heeney MM, Lo J, McAlvin JB, Peeler K, Shah N, Yee CSK, Berry GT, Bodamer O. An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. J Inherit Metab Dis. 2020 Jul;43(4):880-890. doi: 10.1002/jimd.12225. PMID: 32064623 *These authors contributed equally
2019
Burkitt’s Lymphoma presenting as menorrhagia and a vaginal mass in an adolescent.
Wilkie GL, Taggart AA, Prensner JR, Billett AL, Laufer MR. Burkitt’s Lymphoma presenting as menorrhagia and a vaginal mass in an adolescent. Journal of Pediatric and Adolescent Gynecology 2019 Feb;32(1):90-92 PMID: 30278229
2018
Clinically integrated sequencing alters therapy in children and young adults with high-risk glial brain tumors.
Koschmann C, Wu Y, Kumar-Sinha C, Lonigro R, Vats P, Kasaian K, Cieslik M, Cao X, Anderson B, Frank K, Zhao L, Prensner J, Zurieck A, Everett J, Mullan B, Marini B, Camelo-Piragua S, Venneti S, Mc Keever P, McFadden K, Lieberman A, Leonard M, Maher C, Garton H, Muraszko K, Robertson PR, Robinson D, Chinnaiyan A*, and Mody R*. Clinically integrated sequencing alters therapy in children and young adults with high-risk glial brain tumors. JCO Precision Oncology. 2018 May 4;2:PO.17.00133 PMID: 32832832 10.1200/po.17.00133
2017
Oncogenic role for THOR, a conserved cancer/testis long non-coding RNA.
Hosono Y, Niknafs Y.S., Prensner J.R., Iyer M.K., Dhanasekaran S.M., Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu S.C., Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier S.M., Bui H.H., Cao X, Malik R, Johnson T.M., Beer D.G., Feng F.Y., Zhou W, Chinnaiyan A.M. Oncogenic role for THOR, a conserved cancer/testis long non-coding RNA. Cell 2017 Dec 14;171(7):1559-1572. PMID: 29245011
Precision medicine in pediatric oncology: lessons learned and next steps.
Mody R.J.*, Prensner J.R.*, Everett J., Parsons D.W., Chinnaiyan A.M. Precision medicine in pediatric oncology: lessons learned and next steps. Pediatric Blood & Cancer 2017 Mar;64(3). PMID: 27748023 *These authors contributed equally.
2016
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.
Guo H., Ahmed M., Zhang F., Yao C.Q., Li S., Liang Y., Hua J., Soares F., Sun Y., Langstein J., Li Y., Poon C., Bailey S.D., Desai K., Fei T., Li Q., Sendorek D.H., Fraser M., Prensner J.R., Pugh T., Pomerantz M., Bristow R.G., Lupien M., Feng F.Y., Boutros P.C., Freedman M.L., Walsh M.J., He H.H. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics 2016 Oct;48(10):1142-50. PMID: 27526323
The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
Niknafs Y.S., Han S., Ma T., Speers C., Zhang C., Wilder-Romans K., Iyer M.K., Pitchiaya S., Malik R., Hosono Y., Prensner J.R., Poliakov A., Singhal U., Xiao L., Kregel S., Siebenaler R.F., Zhao S.G., Uhl M., Gawronski A., Hayes D.F., Pierce L.J., Cao X., Collins C., Backofen R., Sahinalp C.S., Rae J.M., Chinnaiyan A.M., Feng F.Y. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nature Communications 2016 Sep 26:12791. PMID: 27666543
2015
Integrative clinical sequencing in the management of children and young adults with refractory or relapsed cancer.
Mody R.J., Wu Y.M., Lonigro R.J., Cao X., Roychowdhury S., Vats P., Frank K.M., Prensner J.R., Asangani I., Palanisamy N., Dillman J.R., Rabah R.M., Kunju L.P., Everett J., Raymond V.M., Ning Y., Su F., Wang R., Stoffel E.M., Innis J.W., Roberts J.S., Robertson P.L., Yanik G., Chamdin A., Connelly J.A., Choi S., Harris A.C., Kitko C., Rao R.J., Levine J.E., Castle V.P., Hutchinson R.J., Talpaz M., Robinson D.R., Chinnaiyan A.M. Integrative clinical sequencing in the management of children and young adults with refractory or relapsed cancer. Journal of the American Medical Association. 2015 Sep 1; 314(9):913-25. PMID: 26325560
The landscape of antisense gene expression in human cancers.
Balbin O.A., Malik R., Dhanasekaran S.M., Prensner J.R., Cao X., Wu Y.M., Robinson D., Wang R., Chen G., Beer D.G., Nesvizhskii A.I., Chinnaiyan A.M. The landscape of antisense gene expression in human cancers. Genome Research 2015 Jun 10. 25(7); 1068-79 PMID 26063736
Targeting the MLL complex in castration-resistant prostate cancer.
Malik R., Khan A.P., Asangani I.A., Cieslik M., Prensner J.R., Wang X., Iyer M.K., Jiang X., Borkin D., Escara-Wilke J., Stender R., Wu Y.M., Niknafs Y.S., Jing X., Qiao Y., Palanisamy N., Kunju L.P., Krishnamurthy P.M., Yocum A.K., Mellacheruvu D., Nesvizhskii A.I., Cao X., Dhanasekaran S.M., Feng F.Y., Grembecka J., Cierpicki T., Chinnaiyan A.M. Targeting the MLL complex in castration-resistant prostate cancer. Nature Medicine 2015 Apr; 21(4):344-52. PMID: 25822367
2014
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner J.R., Zhao S., Erho N., Schipper M., Iyer M.K., Dhanasekaran S.M., Magi-Galluzzi C., Mehra R., Sahu A., Siddiqui J., Davicioni E., Den R.B., Dicker A.P., Karnes R.J., Wei J.T., Klein E.A., Jenkins R.B., Chinnaiyan A.M., Feng F.Y. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology 2014 Dec;15(13):1469-80. PMID: 25456366
A novel in situ hybridization assay for the long non-coding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.
Mehra R., Shi Y., Udager A.M., Prensner J.R., Sahu A., Iyer M.K., Cao X., Jiang H., Feng F.Y., Chinnaiyan A.M. A novel in situ hybridization assay for the long non-coding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia 2014 Dec;16(12):1121-1127. PMID: 25499224
The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation though cMyc.
Prensner J.R., Chen W., Han S., Iyer M.K., Cao Q., Kothari V., Evans J.R., Knudsen K.E., Paulsen M.T., Ljungman M., Lawrence T.S., Chinnaiyan A.M., Feng F.Y. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation though cMyc. Neoplasia 2014 Nov 20;16(11):900-8. PMID: 25425964
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E., Chen G., Prensner J.R., Shiratsuchi H., Sam C., Zhao L., Kalemkerian G.P., Brenner D., Lin J., Reddy R.M., Chang A.C., Capella G., Cardenal F., Beer D.G., Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. Journal of Thoracic Oncology 2014 Oct; 9(10):1513-22. PMID 25170638
The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.
Malik R., Patel L., Prensner J.R., Shi Y., Iyer M., Subramaniyan S., Carley A., Niknafs Y.S., Sahu A., Han S., Ma T., Liu M., Asangani I., Jing X., Cao X., Dhanasekaran S.M., Robinson D., Feng F., Chinnaiyan A.M. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Molecular Cancer Research 2014 Aug; 12(8):1081-7 PMID: 25030374
The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.
Prensner J.R., Sahu A., Iyer M.K., Malik R., Chandler B., Asangani I.A., Poliakov A., Vergara I.A., Alshalalfa M., Jenkins R.B., Davicioni E., Feng F.Y., Chinnaiyan A.M. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 2014 Mar 30;5(6):1434-8. PMID: 24727738
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.
Prensner J.R., Chen W., Iyer M.K., Cao Q., Ma T., Han S., Sahu A., Malik R., Wilder-Romans K., Ateeq B., Navone N., Logothetis C.J., Araujo J.C., Pisters L.L., Tewari A.K., Canman C.E., Knudsen K.E., Kitabayashi N., Rubin M.A., Demichelis F., Lawrence T.S., Chinnaiyan A.M. & Feng F.Y. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Research 2014 Mar 15;74(6):1651-60. PMID: 24473064
Before 2014
The lncRNA SChLAP1 coordinates aggressive prostate cancer and antagonizes the SWI/SNF complex.
Prensner J.R., Iyer M.K., Sahu A., Asangani I.A., Cao Q., Patel L., Vergara I.A., Davicioni E., Ehro N., Ghadessi M., Jenkins R.B., Triche T.J., Malik R., Bedenis R., McGregor N., Ma T., Chen W., Han S., Jing X., Cao X., Wang X., Chandler B., Yan W., Siddiqui J., Kunju L.P., Dhanasekaran S.M., Pienta K., Feng F.Y., Chinnaiyan A.M. The lncRNA SChLAP1 coordinates aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics 2013 Nov;45(11):1392-8. PMID: 24076601
Reconstructing targetable lung cancer pathways combining transcriptome, proteome and phosphoproteome.
Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran M., Cao X., Nesvizhskii A.I., Chinnaiyan A.M. Reconstructing targetable lung cancer pathways combining transcriptome, proteome and phosphoproteome. Nature Communications 2013 Oct 18;4:2617. PMID: 24135919
Analysis of the Tau-associated proteome reveals that exchange of Hsp70 for Hsp90 occurs during Tau degradation.
Thompson A.D., Scaglione K.M., Prensner J., Gillies A.T., Chinnaiyan A., Paulson H.L., Jinwal U.K., Dicket C.A., Gestwicki J.E. Analysis of the Tau-associated proteome reveals that exchange of Hsp70 for Hsp90 occurs during Tau degradation. ACS Chemical Biology 2012 Oct 19;7(10):1677-86. PMID: 22769591
The mutational landscape of lethal castration-resistant prostate cancer.
Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., Asangani I.A., Ateeq B., Chun S.Y., Siddiqui J., Sam L., Anstett M., Mehra R., Prensner J.R., Palanisamy N., Ryslik G.A., Vandin F., Raphael B.J., Kunju L.P., Rhodes D.R., Pienta K.J., Chinnaiyan A.M., Tomlins S.A. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012 Jul 12;487(7406):239-43. PMID: 22722839
Expressed pseudogenes in the transcriptional landscape of human cancers.
Kalyana-Sundaram S., Kumar-Sinha C., Shankar S., Robinson D.R., Wu Y.M., Cao X., Asangani I.A., Kothari V., Prensner J.R., Lonigro R.J., Iyer M.K., Barrette T., Shanmugam A., Dhanasekaran S.M., Palanisamy N., Chinnaiyan A.M. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 2012 Jun 22;149(7):1622-34. PMID: 22726445
PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma.
Brenner J.C., Feng F.Y., Han S., Patel S., Goyal S.V., Bou-Maroun L.M., Liu M., Lonigro R.J., Prensner J.R., Tomlins S.A., Chinnaiyan A.M. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Research 2012 Apr 1;72(7):1608-13. PMID: 22287547
Coordinated regulation of polycomb group complexes through microRNAs in cancer.
Cao Q., Mani R.S., Ateeq B., Dhanasekaran S.M., Asangani I.A., Yu J., Kim J.H., Prensner J.R., Brenner J.C., Cao X., Jing X., Wang R., Li Y., Dahiya A., Wang L., Lonigro R.J., Tomlins S.A., Palanisamy N., Maher C.A., Varambally S., Chinnaiyan A.M. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011 Aug 16;20(2): 187-99. PMID: 21840484
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.
Prensner J.R., Iyer M.K., Balbin O.A., Dhanasekaran S.M., Cao Q., Brenner J.C., Asangani I., Grasso C., Kominsky H.D., Cao X., Jing X., Siddiqui J., Wei J.T., Palanisamy N., Robinson D., Iyer H.K., Maher C.A., Chinnaiyan A.M. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology 2011 Jul 31;29(8):742-9. PMID: 21804560
Deep sequencing reveals distinct patterns of DNA methylation and transcript isoform regulation in prostate cancer.
Kim J.H., Dhanasekaran S.M., Prensner J.R., Cao X., Robinson D., Kalyana-Sundaram S., Shankar S., Jing X., Iyer M., Hu M., Sam L., Grasso C., Maher C.A., Palanisamy N., Mehra R., Huang C., Siddiqui J., Yu J., Qin S., Chinnaiyan A.M. Deep sequencing reveals distinct patterns of DNA methylation and transcript isoform regulation in prostate cancer. Genome Research 2011 Jul; 21 (7):1028-41. PMID: 21724842
Characterization of KRAS Rearrangements in Metastatic Prostate Cancer.
Wang X.S., Shankar S., Dhanasekaran S.M., Ateeq B., Sasaki A., Jing X., Robinson D., Cao Q., Prensner J., Yocum A., Wang R., Fries D., Han B., Asangani I., Cao X., Li Y., Omenn G., Pflueger D., Gopalan A., Reuter V., Kahoud E.R., Cantley L., Rubin M., Palanisamy N., Varambally S., Chinnaiyan A.M. Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery 2011 Jun; 1(1): 35-43. PMID: 22140652
The landscape of copy number alterations across multiple cancers.
Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., McHenry K.T., Pinchback R., Ligo A.H., Cho Y.J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J., Liefeld T., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M., DeMichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of copy number alterations across multiple cancers. Nature 2010 Feb 18;463(7283):899-905. PMID: 20164920
Integrative analyses reveal the functional and genetic associations of gene fusions in cancer.
Wang X.S.*, Prensner J.R.*, Chen G., Cao Q., Han B., Dhanasekaran S.M., Ponnala R., Cao X., Varambally S., Thomas D.G., Giordano T.J., Beer D.G., Palanisamy N., Sartor M.A., Omenn G.S., Chinnaiyan A.M. Integrative analyses reveal the functional and genetic associations of gene fusions in cancer. Nature Biotechnology 2009 Nov;27(11):1005-11. PMID: 19881495 *These authors contributed equally.
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson, B.E., Tomlins S.A., Shah N., Laxman B., Cao Q., Prensner J.R., Cao X., Singla N., Montie J.E., Varambally S., Mehra R., Chinnaiyan A.M. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Research 2008;68(1):73-80. PMID: 18172298
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
Beroukhim R., Getz G., Nghiemphu L., Barretina J., Hsueh T., Linhart D., Vivanco I., Lee J., Huang J., Alexander S., Du J., Kau T., Thomas R.K., Shah K., Soto H., Perner S., Prensner J., Debiasi R., Demichelis F., Hatton C., Rubin M., Garraway L.A., Nelson S.F., Liau L., Mischel P., Cloughesy T., Meyerson M., Golub T.A., Lander E.S., Mellinghoff I.K., Sellers W.R. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences 2007;104(50):20007-12. PMID: 18077431